BioSig Appoints Brenda Castrodad to Lead Human Resources
February 16 2021 - 8:45AM
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the
“Company”), a medical technology company commercializing an
innovative signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals, today announced that it appointed Ms. Brenda Castrodad to
lead its Human Resources department.
A seasoned executive, Ms. Castrodad brings a wealth of
experience in leading organizational development in start-ups and
Fortune 500 companies within the life sciences sector. Most
recently, Ms. Castrodad led the HR department at TissueTech, Inc.,
a Miami, FL-based biotech leader in regenerative amniotic
tissue-based products, where she was responsible for transformation
and automation of the company’s HR practices, talent planning, and
team building. Prior to TissueTech, Inc., Ms. Castrodad spent six
years at HeartWare, Inc., a heart failure medtech
company acquired by Medtronic [NYSE:MDT] in 2016 for $1.1
billion. By optimizing the internal talent acquisition
function and aligning business practices, Ms. Castrodad helped grow
the organization from approx. 80 to 500+ staff which achieved
approx. $250 million in revenues before the acquisition. Earlier in
her career, Ms. Castrodad spent 16 years at Schering-Plough Corp, a
pharmaceutical company acquired in 2009 for $41.1 billion by Merck
& Co. [NYSE:MRK]. Ms. Castrodad holds a Master’s Degree in
Public Administration and a Bachelor’s Degree in Social Sciences –
Human Welfare from the University of Puerto Rico and a Labor
Relations Certificate from the University of Michigan.
"A proven champion of culture, growth, and transformation,
Brenda impressed us with her experience in positioning HR as a
strategic business partner to create a platform for successful
talent acquisition and employee engagement. Brenda’s expertise in
supporting rapid growth, combined with her knowledge of our
industry, should be invaluable as we scale up our customer-facing
teams while further developing the in-house talent to drive the
innovation engine. We look forward to working with Brenda as we
prepare the Company for commercial success,” commented Kenneth L.
Londoner, Chairman, and CEO of BioSig Technologies, Inc.
“It is a privilege to join the BioSig team of dedicated and
experienced professionals across the organization. I’m energized by
the company’s culture of innovation and commercialization plans.
I’m thrilled to be a valuable contributor to the incredible
growth path ahead of us,” commented Brenda Castrodad.
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve
signal fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).
The Company’s first product, PURE EPä System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording and
storing of electrocardiographic and intracardiac signals for
patients undergoing electrophysiology (EP) procedures in an EP
laboratory.
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward- looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) the geographic, social and
economic impact of COVID-19 on our ability to conduct our business
and raise capital in the future when needed, (ii) our inability to
manufacture our products and product candidates on a commercial
scale on our own, or in collaboration with third parties; (iii)
difficulties in obtaining financing on commercially reasonable
terms; (iv) changes in the size and nature of our competition; (v)
loss of one or more key executives or scientists; and (vi)
difficulties in securing regulatory approval to market our products
and product candidates. More detailed information about the Company
and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company’s filings
with the Securities and Exchange Commission (SEC), including the
Company’s Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q. Investors and security holders are urged to read these
documents free of charge on the SEC’s website at
http://www.sec.gov. The Company assumes no obligation to publicly
update or revise its forward-looking statements as a result of new
information, future events or otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024